PMID- 23026608
OWN - NLM
STAT- MEDLINE
DCOM- 20130312
LR  - 20151119
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 44
IP  - 8
DP  - 2012 Oct
TI  - Pre- and posttransplant monitoring of alloantibodies by complement-dependent 
      cytotoxicity and luminex methodologies in liver transplantation.
PG  - 2411-2
LID - S0041-1345(12)00701-4 [pii]
LID - 10.1016/j.transproceed.2012.07.005 [doi]
AB  - BACKGROUND: This study evaluated the influence of circulating anti-HLA antibodies 
      on outcomes of 97 liver allografts from deceased donors. METHODS: Human leukocyte 
      antigen (HLA) antibody screening was performed by both complement-dependent 
      cytotoxicity (CDC) and multiparameter Luminex microsphere-based assays (Luminex 
      assay). RESULTS: The agreements between T- and B- cell CDC and Luminex assays 
      were 67% and 77% for pre- and posttransplant specimens, respectively. Graft 
      dysfunction was not associated with either positive pretransplant CDC or Luminex 
      panel-reactive antibody (PRA) values. Likewise, positive posttransplant T- or B- 
      cell CDC PRA values were not associated with graft dysfunction. In contrast, 
      posttransplant Luminex PRA values were significantly higher among patients with 
      graft dysfunction compared with subjects with good outcomes (P = .017). 
      CONCLUSION: Posttransplant monitoring of HLA antibodies with Luminex methodology 
      allowed identification of patients at high-risk for poor graft outcomes.
CI  - Copyright (c) 2012 Elsevier Inc. All rights reserved.
FAU - Monteiro, F
AU  - Monteiro F
AD  - Laboratory of Transplantation Immunology, University of Sao Paulo Medical School, 
      Sao Paulo, Brazil. frmonte@usp.br
FAU - Rodrigues, H
AU  - Rodrigues H
FAU - Kalil, J
AU  - Kalil J
FAU - Castro, M C
AU  - Castro MC
FAU - Panajotopoulos, N
AU  - Panajotopoulos N
FAU - Paredes, M
AU  - Paredes M
FAU - Massarolo, P
AU  - Massarolo P
FAU - Mies, S
AU  - Mies S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Biomarkers)
RN  - 0 (HLA Antigens)
RN  - 0 (Isoantibodies)
SB  - IM
MH  - B-Lymphocytes/immunology
MH  - Biomarkers/blood
MH  - *Complement Activation
MH  - *Cytotoxicity Tests, Immunologic
MH  - *Cytotoxicity, Immunologic
MH  - Fluorescence
MH  - Graft Rejection/blood/diagnosis/*immunology
MH  - HLA Antigens/*immunology
MH  - *Histocompatibility
MH  - Histocompatibility Testing
MH  - Humans
MH  - Isoantibodies/*blood
MH  - Liver Transplantation/*immunology
MH  - Monitoring, Immunologic/*methods
MH  - Predictive Value of Tests
MH  - T-Lymphocytes/immunology
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2012/10/03 06:00
MHDA- 2013/03/13 06:00
CRDT- 2012/10/03 06:00
PHST- 2012/10/03 06:00 [entrez]
PHST- 2012/10/03 06:00 [pubmed]
PHST- 2013/03/13 06:00 [medline]
AID - S0041-1345(12)00701-4 [pii]
AID - 10.1016/j.transproceed.2012.07.005 [doi]
PST - ppublish
SO  - Transplant Proc. 2012 Oct;44(8):2411-2. doi: 10.1016/j.transproceed.2012.07.005.